Home>>Signaling Pathways>> Others>> UDP Glucuronosyltransferases>>Dapagliflozin-3-O-β-D-Glucuronide

Dapagliflozin-3-O-β-D-Glucuronide

Catalog No.GC43376

Dapagliflozin-3-O-β-D-glucuronide is a metabolite of dapagliflozin.

Products are for research use only. Not for human use. We do not sell to patients.

Dapagliflozin-3-O-β-D-Glucuronide Chemical Structure

Cas No.: 1351438-75-9

Size Price Stock Qty
500μg
$197.00
In stock
1mg
$375.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Dapagliflozin-3-O-β-D-glucuronide is a metabolite of dapagliflozin . Dapagliflozin is a first generation selective sodium glucose cotransporter (SGLT) 2 inhibitor that blocks glucose transport.[1]  Dapagliflozin is metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A9 to dapagliflozin-3-O-β-D-glucuronide, which is 2,600-fold less potent than the parent compound with regard to SGLT2 inhibition.[2]

Reference:
[1]. Chao, E.C., and Henry, R.R. SGLT2 inhibition - A novel strategy for diabetes treatment. Nature Reviews.Drug Discovery 9(7), 551-559 (2010).
[2]. van der Walt, J.-S., Hong, Y., Zhang, L., et al. A nonlinear mixed effects pharmacokinetic model for dapagliflozin and dapagliflozin 3-O-glucuronide in renal or hepatic impairment. CPT Pharmacometrics Syst. Pharmacol. 2(e42), 1-9 (2013)

Reviews

Review for Dapagliflozin-3-O-β-D-Glucuronide

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Dapagliflozin-3-O-β-D-Glucuronide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.